Skip to main content
PERCHERON THERAPEUTICS LIMITED logo

PERCHERON THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PER ISIN · AU0000317281 LEI · 984500FF63A961E0K787 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,206 across all filing types
Latest filing 2017-10-30 Interim / Quarterly Rep…
Country AU Australia
Listing ASX PER

About PERCHERON THERAPEUTICS LIMITED

https://percherontx.com

Percheron Therapeutics Limited is a clinical-stage company focused on the development of novel antisense pharmaceuticals for rare diseases. The company's lead program, ATL1102, is an antisense oligonucleotide targeting the CD49d receptor, a subunit of the VLA-4 integrin. This therapeutic candidate is primarily being developed for the treatment of Duchenne muscular dystrophy (DMD), where it aims to reduce inflammation and muscle damage by modulating the immune system's response. Formerly known as Antisense Therapeutics, the firm utilizes its proprietary antisense technology platform to create targeted therapies that inhibit the production of proteins associated with disease progression. The company's research and development efforts are centered on addressing significant unmet medical needs through precision genetic medicine.

Recent filings

Filing Released Lang Actions
Appendix 4C - quarterly 5 pages 794.3KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B' and contains detailed financial data including consolidated statement of cash flows for the current quarter and year to date, cash flow from operating, investing, and financing activities, reconciliation of cash and cash equivalents, payments to directors, financing facilities, estimated cash outflows for the next quarter, and compliance statements. The document covers a quarterly period ending 30 September 2017 and includes substantive financial data and analysis, not just an announcement or certification. This matches the definition of an Interim / Quarterly Report (IR). The document length is 9488 characters, which is sufficient to contain detailed financial information. Therefore, the correct classification is IR with high confidence. Q1 2018
2017-10-30 English
ATL1102 Black Hole MS Data Presented at Gobal Conference 2 pages 236.0KB
Regulatory Filings Classification · 85% confidence The document is a detailed announcement from Antisense Therapeutics Ltd about the presentation of clinical data related to their drug ATL1102 at a scientific conference (the 7th Joint ECTRIMS-ACTRIMS Meeting). It includes detailed clinical trial results, statistical analysis, and references to published medical journal articles. The content focuses on the efficacy of ATL1102 in reducing multiple sclerosis lesions and includes scientific data and conclusions. There is no indication that this is a financial report, regulatory filing, or management discussion. It is not a transcript of a call, nor an announcement of voting results or capital changes. The document is a scientific and clinical data presentation rather than a financial or corporate filing. Given the nature of the content, it best fits under Regulatory Filings (RNS) as a general announcement that does not fit other specific financial or corporate categories.
2017-10-29 English
Notice of Annual General Meeting/Proxy Form/Annual Report 81 pages 3.3MB
AGM Information Classification · 95% confidence The document is titled 'NOTICE OF ANNUAL GENERAL MEETING' and includes details about the meeting date, location, resolutions to be voted on, proxy instructions, and explanatory notes. It references the Annual Financial Report for the year ended 30 June 2017 but does not contain the report itself. The document is a notice sent to shareholders to inform them about the AGM and to solicit their votes on various resolutions, including adoption of the remuneration report, director re-election, and a placement facility. It is not the Annual Report itself, nor is it a voting results announcement or proxy solicitation document. Given the content and purpose, this document fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting, including notices and explanatory notes.
2017-10-26 English
ATL1102 for MS and DMD Update 2 pages 137.3KB
Regulatory Filings Classification · 95% confidence The document is a company announcement dated 17 October 2017 from Antisense Therapeutics regarding updates on clinical trials for ATL1102 for Multiple Sclerosis and Duchenne Muscular Dystrophy. It discusses regulatory interactions with the FDA, trial protocol updates, clinical trial agreements, and upcoming capital raising plans. The content is focused on clinical trial progress and regulatory status rather than financial results, management changes, or shareholder voting. It does not contain financial statements or detailed financial analysis, nor is it a transcript or presentation. The document is an operational update related to clinical development and regulatory processes, which fits best under a general regulatory announcement category. It is not a full report, earnings release, or capital update. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length (6809 characters) and content support this classification with high confidence.
2017-10-16 English
ATL1102 for MS and DMD Update 2 pages 30.0KB
Regulatory Filings Classification · 95% confidence The document is a company announcement dated 2 October 2017 from Antisense Therapeutics Limited regarding updates on clinical trials for ATL1102 for Multiple Sclerosis and Duchenne Muscular Dystrophy. It discusses regulatory approvals, FDA notifications, and trial status updates. There are no financial statements, earnings data, or detailed financial analysis present. The content focuses on clinical trial progress and regulatory status rather than financial results or management commentary. The document is relatively short (6,233 characters) and reads as a regulatory or corporate announcement rather than a full report or presentation. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory or corporate announcements that do not fit other specific categories.
2017-10-01 English
Appendix 4G 13 pages 140.4KB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 4G' and references ASX Listing Rules 4.7.3 and 4.10.3, which pertain to corporate governance disclosures required to be lodged with the ASX alongside the annual report. It includes a detailed key to disclosures against the Corporate Governance Council Principles and Recommendations for the financial year ended 30 June 2017. The document is a formal statement of corporate governance practices, referencing specific pages of the annual report where the corporate governance statement can be found. It is not the annual report itself but a regulatory filing required to accompany the annual report, focusing on governance disclosures. The document is lengthy (15,000 characters) and contains detailed governance information but does not include full financial statements or comprehensive annual report content. Therefore, it fits best as a Regulatory Filing (RNS) related to corporate governance disclosures under ASX rules, rather than the Annual Report (10-K) or Governance Information (CGR) standalone report. The document is a formal regulatory submission to the ASX, fulfilling listing rule requirements.
2017-09-27 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.